Cart 0 Product Products (empty)
No products
Free shipping! Shipping
$0.00 Total
Product successfully added to your shopping cart
Quantity
Unit
Total
There are 0 items in your cart. There is 1 item in your cart.
Total products (tax excl.)
Total shipping (tax excl.) Free shipping!
Total (tax excl.)
Epigenetics
- Protein Control Ligand
- Pathway Inhibitors
- Enzyme Inhibitors
- Kinase Inhibitors
- Protease
- Synthase
- p18
- p38
- p53
- p70
- p90
- Peptidase
- Carboxyl and Decarboxylases
- Ceramide Turnover Enzymes
- Chromatin Modifying Enzymes
- Cyclic Nucleotide Turnover Enzymes
- Glycerophospholipid Turnover Enzymes
- Hydroxylases
- Ubiquitin-Activating Enzyme
- Adenosine Deaminase
- Clathrin
- Nuclease
- p68
- Protein Inhibitors
- Transporter Inhibitors
- Cell Inhibition
- Synthase
- Receptor Tyrosine Phosphatases (RTP)
- Enzyme Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- 5HT Receptors
- Adrenoceptor
- Angiotensin Receptor
- Cannabinoid Receptors
- CCK Receptors
- DA Receptors
- EAA Receptors
- Ghrelin Receptors
- GABA Receptors
- Histamine Receptors
- Leukotriene Receptors
- Metabotropic Glutamate Receptors
- Motilin Receptors
- Muscarinic Receptor
- Neuropeptide Receptors
- Opioid Receptors
- Orexin Receptors
- Orphan Receptors
- Prostanoid Receptors
- Proteinase-Activated Receptors
- Purinergic Receptors
- Ryanodine receptor
- Sigma Receptors
- Thrombin Receptor
- Vaniloid Receptor
- VIP and PACAP Receptors
- Neurotensin Receptors
- Urotensin Receptor
- Imidazoline receptor
- SMO Receptors
- Apelin Receptor
- β-arrestin/β2-adaptin
- KDM4
- Glucocorticoid Receptor
- Laminin Receptor
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
View larger 
Quizartinib
SKP3266
CAS No:950769-58-1
Chemical Name: AC-220; 1-(5-tert-Butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea
Molarity Calculation Cart®
HOW TO ORDER
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 100 | $20.25 | Total: $2,025.00 |
| 1 | 50 | $23.40 | Total: $1,170.00 |
| 1 | 25 | $27.45 | Total: $686.25 |
| 1 | 10 | $32.40 | Total: $324.00 |
| 1 | 5 | $38.25 | Total: $191.25 |
Data sheet
| Molecular Formula | C29H32N6O4S |
| Molecular Weight | 560.67 |
| CAS Numbers | 950769-58-1 |
| Storage Condition | 0°C (short term), -20°C (long term), desiccated |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| Synonym | AC220; AC 220; AC-220; AC010220; AC-010220; AC 010220; AC010220; Quizartinib |
| IUPAC/Chemical Name | 1-(5-(tert-butyl)isoxazol-3-yl)-3-(4-(7-(2-morpholinoethoxy)benzo[d]imidazo[2,1-b]thiazol-2-yl)phenyl)urea |
| InChl Key | InChi Key: CVWXJKQAOSCOAB-UHFFFAOYSA-N |
| InChl Code | InChI=1S/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36) |
| SMILES Code | O=C(NC1=CC=C(C2=CN3C(SC4=CC(OCCN5CCOCC5)=CC=C34)=N2)C=C1)NC6=NOC(C(C)(C)C)=C6 |
| References | 1) Smith CC, etc. Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397. Cancer Discov. 2015 Jun;5(6):668-79. 2) Zorn JA, Wang Q, Fujimura E, Barros T, Kuriyan J. Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220). PLoS One. 2015 Apr 2;10(4):e0121177. 3: Altman K, Sharata H. Catastrophic eruptive keratoacanthomas and squamous cell cancers after treatment with an FLT3 inhibitor quizartinib (AC220). Dermatol Surg. 2015 Apr;41(4):530-1 |
More info
A second-generation FLT3 inhibitor that has shown promising activity in AML in Phase II clinical trials